DRAMAMINE
Pronunciation: dye-men-HYE-dri-nayt


What it isSedating H1 and muscarinic antagonist formulated with a stimulant counter-ion; motion sickness and vestibular nausea.
Why this oneIt treats vestibular nausea, which 5-HT3 antagonists do not.
What limits itAnticholinergic burden and sedation limit use. Prolonged treatment suppresses vestibular compensation and delays recovery.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Prevention/treatment of motion sickness | Adults & children ≥12 y | 1–2 tablets q4–6h | 1–2 tablets q4–6h | 8 tablets/24h |
| Prevention/treatment of motion sickness | Children 6 to <12 y | ½–1 tablet q6–8h | ½–1 tablet q6–8h | 3 tablets/24h |
| Prevention/treatment of motion sickness | Children 2 to <6 y | ½ tablet q6–8h | ½ tablet q6–8h | 1½ tablets/24h |
Renal Undefined
Hepatic Undefined
Do not exceed the age-specific 24-hour maximum.
Available strengths
Pregnancy Undefined
Lactation Undefined
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 25 mg | tab | per unit | not offered | |
| 50 mg | tab | per unit | $0.06/ea | not offered |
NO BOXED WARNINGS
Principal riskAnticholinergic burden and sedation
Defining liabilityMarked sedation and antimuscarinic toxicity